Our findings provide evidence that CBFA2T3 as a novel candidate gene may promote the application of CSF Aβ42 as an early biomarker to the prediction of the conversion from cognitive health to AD and the detection of disease trajectories. This evidence concerns the gene CBFA2T3 and Alzheimer disease.